Orphan Drug Development an Exciting Opportunity to Provide Superior Therapeutics, Lobe Sciences CEO Says
Lobe Sciences (CSE:LOBE,OTCQB:LOBEF) has significantly expanded its portfolio following its acquisition of Altemia & Company. The purchase also sets Lobe Sciences up for revenue generation in the short term, helping…